Table 2.
G6PD activity and genotypes according to the different clinical groups
|
G6PD variant
Legacy name |
Relative proportion of patientsa | Mean G6PD-Activity U/g Hb | Mean G6PD residual activity %b |
|---|---|---|---|
| Group 1. Hospitalization during neonatal period n = 9 | |||
| G6PD A−202A/376G | 4/49 | 3 (1.55–4.60) | 34.1 (17.42–51.66) |
| G6PD A−376G/968C | 3/18 | 1.6 (1.2–2.0) | 17.6 (13.48–22.47) |
| G6PD A−202A/376G (Heterozygous female) | 1/1 | 0.35 | 3.93 |
| Mediterranean | 1/1 | 0.10 | 1.12 |
| Average (min-max) | 1.92 (0.10–4.60) | 21.60 (1.12–51.69) | |
| Group 2. NNJ non-hospitalized, n = 38 | |||
| G6PD A−202A/376G | 21/49 | 2.9 (1.10–4.10) | 32 (12.36–46.07) |
| G6PD A−376G/968C | 10/18 | 1.4 (0.50–2.33) | 15.9 (5.62–26.22) |
| Union-Maewo | 3/6 | 0.1 (0.05–0.10) | 0.8 (0.78–1.12) |
| Akrokorinthos | 1/1 | 2.7 | 29.8 |
| Santamaria | 1/1 | 0.9 | 10.1 |
| Mahidol | 1/1 | 2.7 | 30.3 |
| Viangchan-Jammu | 1/1 | 3.9 | 43.8 |
| Average (min-max) | 2.22 (0.10–4.10) | 24.97 (1.12–46.07) | |
| Group 3. Asymptomatic during the neonatal period, n = 34 | |||
| G6PD A−202A/376G | 24/49 | 2.6 (1.40–4.80) | 29.6 (15.73–53.93) |
| G6PD A−376G/968C | 5/18 | 1.8 (1.20–2.60) | 20.1 (13.48–29.21) |
| Union-Maewo | 3/6 | 0.1 (0.05–0.06) | 0.6 (0.56–0.67) |
| Akrokorinthos | 1/1 | 4.0 | 44.9 |
| Belem | 1/1 | 1.1 | 12.4 |
| Average (min-max) | 2.28 (0.05–4.8) | 25.62 (0.56–53.93) | |
Bold values indicate average (minimum-maximum)
aDenominator means the total number of patients of each variant
bThere were no significant statistical differences among the three study groups (P = 0.707)